elranatamab
Sponsor Pfizer INC · listed as PFE
elranatamab is a drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Aug 4, 2027 (day precision, medium confidence), tied to trial NCT05317416. That trial is in Phase 3 and currently active not recruiting, studying Multiple Myeloma. It appears across 6 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for elranatamab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05020236 | Phase 3 | Recruiting | 2026-02-26 | Experimental | Pfizer | Multiple Myeloma |
| NCT06152575 | Phase 3 | Recruiting | 2026-08-30 | Experimental | Pfizer | Multiple Myeloma |
| NCT05317416 catalyst | Phase 3 | Active, not recruiting | 2027-08-04 | Experimental | Pfizer | Multiple Myeloma |
| NCT07647432 | Phase 2/3 | Not yet recruiting | 2029-12-01 | Experimental | University of Illinois at Chicago | Plasmablastic Lymphoma; Hiv; Consolidation |
| NCT05623020 | Phase 3 | Recruiting | 2030-10-18 | Experimental | Pfizer | Multiple Myeloma |
| NCT06918002 | Phase 3 | Recruiting | 2036-05 | Experimental | Intergroupe Francophone du Myelome | Multiple Myeloma, Newly Diagnosed |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More PFE catalysts